Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2074-2083

  Nonomura, Yoshinori ^a,b   Nagasaka, Kenji ^a   Hagiyama, Hiroyuki ^a   Sekine, Chiyoko ^a,b   Nanki, Toshihiro ^a   Tamamori Adachi, Mimi ^a   Miyasaka, Nobuyuki ^a   Kohsaka, Hitoshi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2C; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P16INK4A; PROTEIN P18; RETINOBLASTOMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; UNCLASSIFIED DRUG;

ARTICLE; CDKI GENE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; FIBROBLAST; GENE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; UPREGULATION;

ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 3; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; SYNOVIAL MEMBRANE;

EID: 33745876853     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21927     Document Type: Article

References (40)

1. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101-6.
2. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999;26:17-719.
3. Andreakos E, Foxwell B, Brennan F, Maini R, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002;13:299-313.
4. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999;5:760-7.
5. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000;165:7246-52.
6. Cip1 gene into the joints. Int Immunol 2001;13:723-31.
7. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
8. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003;171:4913-19.
9. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996;381:804-6.
10. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003;170:838-45.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. J Am Soc Nephrol 1997;8:51-60.
13. Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. Biochem Biophys Res Commun 1998;247:146-53.
14. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999;10:2013-7.
15. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998;9:2577-83.
16. Tamamori-Adachi M, Ito H, Nobori K, Hayashida K, Kawauchi J, Adachi S, et al. Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy. Biochem Biophys Res Commun 2002;296:274-80.
17. Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, et al. Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res 2003;92:e12-9.
18. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-22.
19. Terao R, Honda K, Hatano E, Uchara T, Yamamoto M, Yamaoka Y. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract. Hepatology 1998;28:605-12.
20. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001;8:730-5.
21. Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, et al. An investigation of cell proliferation and soluble mediators induced by interleukin 1β in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res 2001;50:65-72.
22. Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle DJ, Johnson SR. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br J Pharmacol 2004;142:1318-24.
23. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U. et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004;172:1256-65.
24. Zhong H, Simons JW. Direct comparison of GAPDH, β-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999;259:523-26.
25. Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, et al. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 2003;46:2027-30.
26. WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression. J Cell Sci 1998;111:2247-55.
27. Bradley K, Scatizzi JC, Flore S, Shamiyeh E, Koch AE, Firestein GS, et al. Retinoblastoma suppression of matrix metalloproteinase 1, but not interleukin-6, through a p38-dependent pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004;50:78-87.
28. Okada Y. Proteinases and matrix degradation. In: Ruddy S, Harris ED Jr, Sledge CB, Budd RC, Sergent JS, editors. Kelley's textbook of rheumatology, 6th ed. Philadelphia: WB Saunders: 2001. p. 55-72.
29. Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002;61:975-80.
30. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-60.
31. 342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum 1999;42:2074-84.
32. Hamada T, Arima N, Shindo M, Sugama K, Sasaguri Y, Brewster M, et al. Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase- inhibitor Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 2000;131:1513-20.
33. Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840: suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. Eur J Pharmacol 2005;508:239-47.
34. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, et al. Ro 32-3555. an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997;121:540-6.
35. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
36. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein I (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997;186:131-7.
37. Wolff B, Naumann M. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB. Oncogene 1999;18:2663-6.
38. Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991;10:1127-34.
39. White LA, Maute C, Brinckerhoff CE. ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) arc auxiliary elements that regulate basal and phorbol-induced transcription. Connect Tissue Res 1997;36:321-35.
40. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.